Glenmark Life Sciences’ share sale via initial public offering (IPO) was oversubscribed by 5.78 times on Wednesday, July 28 – the second day of its issue. The public offer opened for subscription on July 27 and will close tomorrow – July 29, remaining open for investors for a period of three days. On the first day of its issue, the IPO was fully subscribed within hours of opening.
On Wednesday, retail individual investors showed massive interest as the portion reserved for them was subscribed 9.28 times – the highest among the three groups of investors. The portion set aside for non-institutional investors (NII) was subscribed 3.39 times, while the portion reserved for qualified institutional buyers (QIB) was subscribed 1.38 times.
Glenmark Life Sciences’ Rs 1,513 crore IPO consists of a fresh issue of Rs 1,060 crore and an offer for sale of Rs 453.60 crore by its promoters. The leading manufacturer of active pharmaceutical ingredients (API) is selling shares in the price band of Rs 695-720 per equity share. Incorporated in 2011, the company manufactures and develops APIs for cardio-vascular disease, pain management, diabetes, central nervous system disease, among others.
The company will utilise the IPO proceeds to make the payment of the outstanding purchase consideration to the promoter for the spin-off of the API business. It will also use funds to finance thecapital expenditure requirements and to meet general corporate purposes.
”As part of expansion plans, Glenmark plans to increase the API manufacturing capabilities enhancing the existing production capacities at Ankleshwar facility by FY22 and Dahej facility by FY22-FY23 to an aggregate annual total installed capacity of 200 KL.
At the higher end of the price band, Glenmark Pharma is reasonably priced at a P/E ratio of 25.09 times FY21 EPS (on a fully diluted on post-issue basis). This is lower as compared to peers such as Divi’s lab (64 times), Laurus Labs (37 times) and Shilpa Medicare (33 times). Glenmark Life has also reported higher return ratios than these companies.
Given factors such as strong growth in topline, healthy bottom-line expansion, robust margins, industry-leading return ratios, leadership position in APIs, and reasonable valuations, we remain positive on the prospects of this issue,” SEBI-registered investment advisor INDmoney said in a report.